Abstracts tagged "glucocorticoids"

Abstract Number: 1045 • 2013 ACR/ARHP Annual Meeting
Under Reporting Of Cataracts In Randomised Controlled Trials Investigating The Use Of Systemic Glucocorticoids In Patients With Rheumatoid Arthritis
Rachel J. Black^1,2 and William G. Dixon³, ¹Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ²Department of Medicine, The University of Adelaide, Adelaide, Australia, ³The University of Manchester, Manchester, United Kingdom
Background/Purpose: Oral glucocorticoid (GC) therapy is used in more than half of patients with rheumatoid arthritis (RA). Cataracts are a recognised treatment-related side effect of…
Abstract Number: 746 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Treatment and Damage In The Antineutrophil- Cytoplasm Antibody Associated Vasculitides
Joanna Robson¹, Helen Doll², Ravi Suppiah³, Oliver Flossmann⁴, Lorraine Harper⁵, Peter Hoglund⁶, David Jayne⁷, Alfred Mahr⁸, Kerstin Westman⁹ and Raashid A. Luqmani¹⁰, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ²Department of Population Health, University of East Anglia, Norwich, United Kingdom, ³Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand, ⁴Nephrology, Royal Berkshire Hospital, Reading, United Kingdom, ⁵Nephrology, University of Birmingham, Birmingham, United Kingdom, ⁶Competence Centre fo Clinical Research, Skane University Hospital, Lund, Sweden, ⁷Vasculitis and Lupus Clinic, Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, ⁸Department of Internal Medicine, Hospital Saint-Louis, Paris, France, ⁹Nephrology and Transplantation, Skåne University Hospital Malmö, Lund University, Malmö, Sweden, ¹⁰Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis [Wegener's] (GPA) and microscopic polyangiitis (MPA) are antineutrophil-cytoplasm antibody associated vasculitides (AAVs). Damage is quantified by the Vasculitis Damage Index (VDI).…
Abstract Number: 747 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Glucocorticoids To Treat Limited Flares In ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A. Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, Vasculitis Center, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: The great majority of patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) achieve disease remission initially, but relapses occur in up to…
Abstract Number: 492 • 2013 ACR/ARHP Annual Meeting
Distinction Between Glucocorticoid-Responders and Non-Responders In Rheumatoid Arthritis: A New Role For Endoplasmic Reticulum Aminopeptidase 2
Ruth Fritsch-Stork¹, Sandra Cardoso¹, Jasper Broen¹, Marian Groot-Koerkamp², Arno Concepcion¹, Floris Lafeber¹ and Johannes W.J. Bijlsma¹, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Molecular Cancer Research, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Glucocorticoids (GC) have been a cornerstone of Rheumatoid arthritis (RA)-therapy for the last decades. However, about a third of RA-patients do not respond adequately.…
Abstract Number: 103 • 2013 ACR/ARHP Annual Meeting
Proportion Of U.S. Older Adults Meeting Inclusion Criteria For 2010 ACR Recommendations On Glucocorticoid-Induced Osteoporosis
Robert A. Overman^1,2, Joshua C. Toliver³, Jun-Yen Yeh⁴, Margaret L. Gourlay⁵ and Chad L. Deal⁶, ¹Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, ²Rheumatology, Cleveland Clinic, Cleveland, OH, ³Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, ⁴Arnold & Marie Schwartz College of Pharmacy and Health Sciences - Divison of Pharmaceutical Sciences, Long Island University, Brooklyn, NY, ⁵Family Medicine, University of North Carolina, Chapel Hill, NC, ⁶Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Glucocorticoid-induced osteoporosis (GIO) is the most common cause of secondary osteoporosis. Fracture related to GIO increases a patient’s mortality risk and reduces quality of…
Abstract Number: 55 • 2013 ACR/ARHP Annual Meeting
Glucocorticoid Receptor Modulator Compound A Does Not Induce Leptin In Human Osteoarthritic Synovial Fibroblasts and In Dedifferentiated Chondrocytes
Olivier Malaise¹, Biserka Relic², Edith Charlier¹, Mustapha Zeddou¹, Florence Quesada-Calvo³, Sophie Neuville⁴, Dominique de Seny² and Michel G. Malaise², ¹Department of Rheumatology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ²Department of Rheumatology, GIGA Research - University of Liège - CHU of Liège, Liège, Belgium, ³Gastroenterology, GIGA Research - University of Liège - CHU Liège, Liège, Belgium, ⁴GIGA Research - University of Liège - CHU of Liège, Liège, Belgium
Background/Purpose: Leptin is generally considered detrimental in osteoarthritis (OA) as it can induce IL-8 in synovial fibroblasts (SF) and matrix metalloproteinases in chondrocytes. We recently…
Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Kim Hørslev-Petersen¹, Merete Lund Hetland², Peter Junker³, Jan Pødenphant⁴, Torkell Ellingsen⁵, Palle Ahlqvist⁶, Hanne M. Lindegaard⁷, Asta Linauskas⁸, Annette Schlemmer⁹, Mette Y. Dam¹⁰, Ib Hansen¹¹, Tine Lottenburger⁶, Anette Jørgensen¹², Sophine B. Krintel¹³, Johnny Raun¹⁴, Christian G. Ammitzbøll¹⁰, Julia Johansen¹³, Mikkel Østergaard¹⁵ and Kristian Stengaard-Pedersen¹⁰, ¹Institute of Regional Health Services Research, University of Southern Denmark, Graasten, Denmark, ²DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark, ³University of Southern Denmark, Odense, Denmark, ⁴Copenhagen University at Gentofte, Hellerup, Denmark, ⁵Silkeborg Regional Hospital, Silkeborg, Denmark, ⁶University of Southern Denmark, Vejle, Denmark, ⁷Department of Rheumatology, Odense University Hospital, Odense, Denmark, ⁸Vendsyssel Hospital, Hjørring, Denmark, ⁹Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁰Arhus University Hospital, Aarhus, Denmark, ¹¹Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹²Rheumatology, Arhus University Hospital, Aarhus, Denmark, ¹³Copenhagen University and Glostrup Hospital, Copenhagen, Denmark, ¹⁴University of Southern Denmark, Graasten, Denmark, ¹⁵Copenhagen University Hospital Glostrup, Copenhagen, Denmark
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…
Abstract Number: 2077 • 2012 ACR/ARHP Annual Meeting
IL-6 Blockade Augments the Anti-Inflammatory Effect without Increasing the Side Effects of Steroids in Collagen-Induced Arthritis
Miho Suzuki¹, Hiroto Yoshida², Misato Hashizume¹, Masashi Shiina², Keisuke Tanaka¹ and Yoshihiro Matsumoto¹, ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan
Background/Purpose: Steroids are the main therapy for chronic inflammatory diseases. They are very effective, but induce many side effects, such as osteoporosis, making it important…
Abstract Number: 2057 • 2012 ACR/ARHP Annual Meeting
Analysis of the Adherence to the Monitoring of Glucocorticoid Eye Toxicity and of the Prevalence of Cataracts and Glaucoma Among Patients with Systemic Lupus Erythematosus
Linda Carli¹, Chiari Tani¹, Francesca Querci², Alessandra Della Rossa¹, Sabrina Vagnani³, Anna d'Ascanio⁴, Rossella Neri⁵, Antonio Tavoni⁶, Stefano Bombardieri³ and Marta Mosca¹, ¹Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy, ³Department of Internal Medicine, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ⁴Department of Internal Medicine, University of Pisa, Rheumatology Unit, Department of Internal Medicine, University of Pisa, PISA, Italy, ⁵University of Pisa, Rheumatology Unit, Pisa, Italy, ⁶Dept of Internal Medicine, Immunoallergology Unit, Department of Internal Meicine, University of Pisa, PISA, Italy
Background/Purpose: Cataracts and glaucoma are among the main causes of impaired visual acuity and have a prevalence respectively of 9-17% and 1-2% among subjects older…
Abstract Number: 1996 • 2012 ACR/ARHP Annual Meeting
Are Changes in Bone Mineral Density Different Between Groups of Early Rheumatoid Arthritis Patients Treated According to a Tight Control Strategy with or without Prednisone, If Osteoporosis Prophylaxis Is Applied?
Marlies C. van der Goes¹, Johannes W.G. Jacobs¹, Maud S. Jurgens¹, Marije F. Bakker¹, Maaike J. van der Veen², Jacobine H. van der Werf³, Paco M.J. Welsing¹ and Johannes W.J. Bijlsma¹, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology, St. Jansdal hospital, Harderwijk, Netherlands, ³Rheumatology, Diakonessenhuis, Utrecht, Netherlands
Background/Purpose: To describe effects on bone mineral density (BMD) of treatment according to EULAR guidelines with a methotrexate-based tight control strategy including 10 mg prednisone…
Abstract Number: 1972 • 2012 ACR/ARHP Annual Meeting
Assessment of Fracture Risk in Postmenopausal Women with Rheumatoid Arthritis
Sina Esmaeilzadeh, Nurten Eskiyurt, Ekin Sen and Merih Akpinar, Physical Medicine and Rehabilitation, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: The aim of this study is to determine the risk of osteoporotic fracture in postmenopausal women with rheumatoid arthritis (RA) and to examine the…
Abstract Number: 1978 • 2012 ACR/ARHP Annual Meeting
A Web-Based Intervention Aimed to Improve Bone Health Among Individuals On Chronic Glucocorticoids
Amy H. Warriner¹, Ryan C. Outman², Nathan Markward³, Ronald Aubert³, Jeffrey R. Curtis⁴, Robert Epstein³, Felix Freuh³, Julia McEachern³, David T. Redden⁵, Monika M. Safford², Eric Stanek³, Amy Steinkellner³ and Kenneth G. Saag⁶, ¹Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, ²Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Medco, Bethesda, MD, ⁴Rheumatology & Immunology, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Biostatistics, University of Alabama at Birmingham, Birmingham, AL, ⁶Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL
Background/Purpose: Despite a significant associated fracture risk, previous population-based studies document low osteoporosis treatment rates for individuals treated with chronic glucocorticoids (GCs) at risk for…
Abstract Number: 1946 • 2012 ACR/ARHP Annual Meeting
Effect of Immunosuppressive Treatment On Gene Expression in Patients with Polymyositis and Dermatomyositis
Ingela M. Loell¹, Yi-Wen Chen², Marina Korotkova³, Kanneboyina Nagaraju² and Ingrid E. Lundberg⁴, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ²Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, ³Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) muscle tissue is characterized by infiltrating T cells, macrophages and dendritic cells, as well as cytokines and chemokines. In…
Abstract Number: 1696 • 2012 ACR/ARHP Annual Meeting
Quantitative Evaluation of Dermal Atrophy by High-Resolution Ultrasonography, Comparing Between Patients Under Long-Term Treatment with Prednisolone or Methylprednisolone
Tim Pottel¹, Christoph Schäfer² and Gernot Keyßer², ¹Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06114 Halle (Saale), Germany, ²Universitätsklinikum Kröllwitz, Department of Internal Medicine II, 06120 Halle (Saale), Germany
Background/Purpose: The katabolic effects of a systemic treatment with glucocorticoids can lead to a progressive atrophy of the skin. Clinical observation suggests a more pronounced…
Abstract Number: 1241 • 2012 ACR/ARHP Annual Meeting
Glucocorticoid use Is associated with increase in HDL in Rheumatoid Arthritis Patients
Lisa L. Schroeder¹, Xiaoqin Tang², Mary Chester M. Wasko³ and Androniki Bili⁴, ¹Rheumatology, Geisinger Health System, Danville, PA, ²Biostatistics, Geisinger Center for Health Research, Danville, PA, ³West Penn Allegheny Health System, Temple University School of Medicine, Pittsburgh, PA, ⁴Rheumatology, Geisinger Medical Center, Danville, PA
Glucocorticoid use is associated with increase in HDL in Rheumatoid Arthritis PatientsBackground/Purpose: Atherogenic lipid profiles are common in active RA, with most common being decreased…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].